Viewing Study NCT06620094



Ignite Creation Date: 2024-10-26 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 3:41 PM
Study NCT ID: NCT06620094
Status: COMPLETED
Last Update Posted: None
First Post: 2024-09-24

Brief Title: The EFFECT of MOBILE APPLICATION USE on DIABETES CONTROL in DIABETIC PATIENTS
Sponsor: None
Organization: None

Study Overview

Official Title: The EFFECT of MOBILE APPLICATION USE on DIABETES CONTROL in DIABETIC PATIENTS
Status: COMPLETED
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: ObjectiveThis study aims to determine the effect of a mobile application on diabetes control in patients with Type 2 diabetes

MethodsThis study is a randomized controlled trial with a pre-test and post-test design The study population consists of Type 2 diabetes patients who applied to the Endocrinology Clinic of Malatya Turgut Özal Medical Center A total of 70 participants were included in the study Data were collected face-to-face using a demographic data collection form a diabetes diagnosis and follow-up form and the Turkish Multidimensional Diabetes Scale The data were analyzed using paired t-tests and independent samples t-tests to compare means counts and percentages in dependent and independent groups
Detailed Description: Type of Study This study is a pre-test post-test randomized controlled experimental study

Population and Sample of the Study The population of the study consisted of individuals with type 2 diabetes who applied to the Endocrinology Clinic of Malatya Inonu University Turgut Ozal Medical Center between May 2021 and December 2021 The sample included patients who met the inclusion criteria during the dates of the study and who applied to the Endocrinology Clinic The power analysis used to determine the sample size was calculated with a 5 margin of error 95 confidence interval at a two-sided significance level and 80 population representation capacity with 50 diabetic individuals for each group 50 experimental 50 control However the study was completed with 38 individuals in the experimental group and 32 in the control group

Inclusion Criteria

Having been diagnosed with type 2 diabetes mellitus for at least 6 months Being between the ages of 40-65 Receiving oral antidiabetic treatment Having an A1C value between 7-10 Owning a mobile phone capable of receiving and playing video messages Not having sensory impairments such as hearing or speech loss or psychiatric problems that prevent communication

Exclusion Criteria

Inability to use the mobile application Patients with a psychological diagnosis according to records Patients using insulin Having an A1C value above 10 Having an infection requiring medication Randomization Care was taken to ensure that the two groups were homogeneous by considering all variables The assignment of diabetic patients to the experimental and control groups was done through randomization to avoid bias The randomization was carried out using the Random Integer Generator method in the Numbers section of the randomorg website where columns with five groups between 1-100 were generated Patients who applied to the Endocrinology Clinic were randomized to numbers 1 and 2 based on which they were assigned to the groups The determination of which number corresponded to the experimental or control group was made by drawing lots at the beginning of the study

Data Collection Tools Two data collection tools were used to collect the data

Diabetes Patient Identification and Monitoring Form This form prepared by the researchers with the help of literature reviews and expert opinions consists of three parts The first part contains 11 items used to determine the socio-demographic characteristics of the patient The second part consists of 32 items that question the patients diabetes-related characteristics such as diabetes type treatment method complications treatment follow-up routines nutrition exercise routines foot care diabetes-related knowledge and habits The third part consists of 9 items that question the metabolic control characteristics of diabetic individuals such as fasting blood sugar A1C total cholesterol LDL HDL triglycerides blood pressure height weight and body mass index

Turkish Multidimensional Diabetes Questionnaire T-MDQ This scale was developed by Talbot and colleagues in 1997 The Turkish validity and reliability of the scale were conducted by Coşansu and Erdoğan in 2010 The scale consists of 40 items 7 sub-dimensions and 3 sections The scale has no total score and each sub-dimension is evaluated separately

Section Focuses on the general perception of diabetes and social support This section consists of three sub-dimensions and 16 items The Perceived Barrier sub-dimension consists of 9 items questioning how much the patientamp39s daily activities such as work social and leisure activities are negatively affected and limited due to diabetes The Perceived Severity consists of 3 items measuring the degree of the patientamp39s perception of the seriousness of diabetes The Perceived Social Support sub-dimension consists of 4 items questioning the patientamp39s perceived social support from important people in their life such as family friends and healthcare professionals In the first section responses are obtained with a 7-point Likert scale 0-none 6-very much The scores of the items answered by the individual for each sub-dimension are summed and divided by the number of items answered to obtain an average score Higher scores indicate higher perceived barriers social support and severity levels

Section Investigates the behaviors of the patients spouse or someone significant to them that either support or fail to support the patients self-care activities for diabetes This section consists of two sub-dimensions and 12 items Positive Supportive Behaviors consist of 8 items aimed at identifying positive behaviors of the patientamp39s spouse or significant other that support the patientamp39s management of diabetes The Misleading Supportive Behaviors sub-dimension consists of 4 items aimed at identifying supportive but bothersome and unhelpful behaviors of the patientamp39s spouse or significant other Responses in the second section are recorded on a 7-point Likert scale 0-never 6-always Individuals living alone do not fill out this section

Section Measures the individualamp39s perception of self-efficacy and outcome expectations related to disease management This section consists of two sub-dimensions and 13 items The Perceived Self-Efficacy sub-dimension consists of 7 items that determine the individuals confidence in performing self-care activities for their illness Responses are recorded on a Likert scale 0-not confident at all 100-very confident The Perceived Outcome Expectation sub-dimension consists of 6 items that evaluate the individualamp39s perception of the effectiveness of self-care behaviors and treatment in achieving metabolic control and preventing complications Responses are recorded on a Likert scale 0-not important at all 100-very important Higher scores indicate higher perceived self-efficacy and outcome expectations

Data Collection The data of the study were collected through face-to-face interviews by the researcher with type 2 diabetic patients who applied to the Endocrinology Clinic between May 2021 and December 2021 Patients meeting the inclusion criteria were included in the study

Initially data collection forms survey form and T-MDQ were applied to the patients in the experimental and control groups Additionally patientsamp39 test results A1C glucose total cholesterol HDL LDL triglycerides blood pressure height and weight measurements were recorded during routine outpatient follow-ups The experimental group received education and follow-up for three months through a mobile application prepared for diabetic patients At the end of this period the T-MDQ routine test results A1C glucose total cholesterol HDL LDL triglycerides blood pressure height and weight measurements were applied again to both the experimental and control groups

Intervention During the initial interview with the experimental group participants were informed about notifications and diabetes education videos that would be sent to their phones Following this notifications were sent three times a day every day of the week The first notification asked the patient to measure and record their fasting and postprandial blood sugar in the morningamp34 the second instructed to amp34exercise for at least 30 minutes a dayamp34 and the third asked them to amp34record the foods and amounts they ate measure and record their evening fasting and postprandial blood sugar and measure and record their blood sugar before going to bedamp34 The results of their routine outpatient tests A1C BMI total cholesterol HDL LDL triglycerides blood pressure and weight measurements were recorded In addition three times a week participants were asked to amp34measure and record their blood pressure and weight and log the recorded information in the app each time During the three-month period individuals continued their routine outpatient follow-ups

Control Group During the first meeting after being informed about the study data collection forms survey form and Turkish Multidimensional Diabetes Questionnaire were applied to the control group The results of the routine outpatient tests A1C glucose total cholesterol HDL LDL triglycerides were recorded Blood pressure height and weight measurements were taken and the first interview was completed The control group continued their routine outpatient follow-ups During the second meeting which took place three months later the data collection forms were applied again The results of routine outpatient tests A1C BMI total cholesterol HDL LDL triglycerides were written down and blood pressure and weight measurements were taken and recorded

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None